• news.cision.com/
  • Attana/
  • Attana introduces Attana Virus Analytics to support global COVID-19 testing efforts

Attana introduces Attana Virus Analytics to support global COVID-19 testing efforts

Report this content

Since the advent of the COVID-19 outbreak Attana has been engaged by select customers to assist in their development of novel vaccine candidates and potential virus treatments. In these efforts, Attana instruments have routinely been used to analyze serum samples in real time, generating in-depth data of both virus and antibody presence.

Given the strong global demand for COVID-19 testing and in particular, accurate antibody testing, Attana has introduced Attana Virus Analytics (AVA) and commenced discussions with various potential customers including international government entities and technology partners.

Covid-19 antibody testing has proven to be challenging using conventional technologies. The benefit of the AVA platform is that instead of searching for a specific antibody as most current tests do, AVA identifies all COVID-19 antibodies and serum molecules that interact with the spike protein from a serum sample. The process involves immobilizing a COVID-19 spike protein on the Attana sensor chip and then as serum samples interact with this surface protein, any antibodies that bind to the protein are identified in real-time. This not only gives a binary yes/no response as to the presence of COVID antibodies, but can also provide the type, quantity and quality of the antibodies present in each serum sample.

The AVA platform consists of the latest Attana instrument, reagents, sensor chips, protocols, instrument training and support, to ensure that laboratory customers can commence testing and initially perform more than 500 serological tests per day, on a single system.

For more information, please contact:

Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com 
tel: + 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact  sales@attana.com





Documents & Links